Abstract

Research Article

Evaluation of Thyroid and Lipid Profile of Hiv Patients Seen in a Faith-Based Health Facility in Anambra State, Nigeria

FU Ukodei*, NK Nnamah, AJ Onuegbu, CE Onah and OB Ezenwa and AN Adimuo

Published: 01 August, 2023 | Volume 7 - Issue 1 | Pages: 014-020

Background: Human Immunodeficiency Virus (HIV) and thyroid function have been described. Prevalence pattern and atherogenic status significantly differ from HIV-negative control in several studies. Unfortunately, few studies have determined the prevalence of thyroid function and lipids among Nigerians living with HIV. 
Objective: This study is to evaluate thyroid hormones and lipid profiles in HIV-positive subjects attending a faith-based health facility in Anambra State Nigeria.
Materials and methods: The serum concentration of Thyroid Stimulating Hormone (TSH), free Triiodothyronine (fT3), triiodothyronine (T3), free Thyroxine (fT4), Thyroxine (T4), Total Cholesterol [TC], Triglyceride [TG], High-Density Lipoprotein [HDL], Low-Density Lipoprotein [LDL] and Very Low-Density Lipoprotein [VLDL] was determined in 95 HIV positive subjects which include 48 patients who were on HAART- group 1 and 47 not on HAART- group 2; and compared to 30 HIV negative controls – group 3. 
Results: The level of TSH and fT3 was significantly (p < 0.05) higher in group 1 participants than in group 2 and the group 3 participants. The level of T4 was significantly higher in group 2 than in group 1 and group 3 participants. The level of T3 was significantly lower in Control participants in comparison to both HAART and non-HAART participants. The prevalence of fT4 dysfunction across the groups was significantly different from each other. The total mean of Cholesterol (163.5 ± 22.7), Triglyceride (163.5 ± 22.7), and Very Low-Density Lipoprotein (14.2 ± 2.4) of the HIV-positive participants were significantly (p < 0.05) lower than that of the HIV negative participants.
Conclusion: The results obtained from this study indicate that serum levels of thyroid hormones may be used as baseline periodic markers during antiretroviral therapy and many people living with HIV may benefit from supplementation if appropriate.

Read Full Article HTML DOI: 10.29328/journal.acem.1001028 Cite this Article Read Full Article PDF

Keywords:

HIV; HAART; Thyroid hormones; Lipid profile; Anambra; Nigeria

References

  1. Achila OO, Abrhaley F, Kesete Y, Tesfaldet F, Alazar F, Fisshaye L, Gebremeskel L, Mehari R, Andemichael D. Dyslipidemia and associated risk factors among HIV/AIDS patients on HAART in Asmara, Eritrea. PLoS One. 2022 Jul 1;17(7):e0270838. doi: 10.1371/journal.pone.0270838. PMID: 35776747; PMCID: PMC9249179.
  2. In Danger: UNAIDS Global AIDS Update 2022. https://www.unaids.org/en/resources/documents/2022/in-danger-global-aids-update (accessed October 10, 2022).
  3. Miller V, Hodder S. Beneficial impact of antiretroviral therapy on non-AIDS mortality. AIDS. 2014 Jan 14;28(2):273-4. doi: 10.1097/QAD.0000000000000079. PMID: 24413312.
  4. Abudiore O, Amamilo I, Campbell J, Eigege W, Harwell J, Conroy J, Jiboye J, Lufadeju F, Amole C, Wiwa O, Anweh D, Agbaji OO, Akanmu AS. High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria. PLoS One. 2023 May 17;18(5):e0284767. doi: 10.1371/journal.pone.0284767. PMID: 37196012; PMCID: PMC10191360.
  5. Ebuehi OAT, Awolola A, Akanmu AS. Changes in Serum Cortisol. Thyroid Hormones and Lipid Profiles in Nigerian Men and Women on 1st and 2nd Line Antiretroviral Therapy for 52 Weeks. International Journal of Virology and Molecular Biology. 2015;4:1; 12-18. doi: 10.5923/j.ijvmb.20150401.03.
  6. Tebit DM, Lobritz M, Lalonde M, Immonen T, Singh K, Sarafianos S, Herchenröder O, Kräusslich HG, Arts EJ. Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors. J Virol. 2010 Oct;84(19):9817-30. doi: 10.1128/JVI.00991-10. Epub 2010 Jul 14. PMID: 20631150; PMCID: PMC2937803.
  7. da Silva Gar, Azevedo MCVM, Motta RN, Pinto JFC, Sa Cam, Ferry FRA. Herpes zoster ophthalmicus as a manifestation of immune reconstitution syndrome in an AIDS patient. Case Report Cad Bras Med. 2012; 25:15-8.
  8. Naing L, Winn T, Rusli BN. Practical Issues in Calculating the Sample Size for Prevalence Studies. Medical Statistics. Archives of Orofacial Sciences. 2006; 1:9-14. https://www.scribd.com/doc/63105077/How-to-Calculate-Sample-Size
  9. Hopton MR, Harrop JS. Immunoradiometric assay of thyrotropin as a "first-line" thyroid-function test in the routine laboratory. Clin Chem. 1986 Apr;32(4):691-3. PMID: 2420488.
  10. Chopra IJ, Nelson JC, Solomon DH, Beall GN. Production of antibodies specifically binding triiodothyronine and thyroxine. J Clin Endocrinol Metab. 1971 Mar;32(3):299-308. doi: 10.1210/jcem-32-3-299. PMID: 4100188.
  11. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974 Apr;20(4):470-5. PMID: 4818200.
  12. Roeschlau P, Bernt E, Gruber W. Enzymatic determination of total cholesterol in serum. Z Klin Chem Klin Biochem. 1974 May;12(5):226. PMID: 4440114.
  13. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 1973 May;19(5):476-82. PMID: 4703655.
  14. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499-502. PMID: 4337382.
  15. Ayodele OE, Akinboro AO, Akinyemi SO, Adepeju AA, Akinremi OA, Alao CA, Popoola AA. Prevalence and clinical correlates of metabolic syndrome in Nigerians living with human immunodeficiency virus/acquired immunodeficiency syndrome. Metab Syndr Relat Disord. 2012 Oct;10(5):373-9. doi: 10.1089/met.2012.0050. Epub 2012 Jul 16. PMID: 22799758.
  16. Reng SR, Uloko EA, Puepet HF, Onwuegbuzie AG, Ramalan AM. Prevalence and determinants of glucose intolerance among HIV/AIDS patients in north-central Nigeria. Niger J Med. 2016 Apr-Jun;25(2):128-32. PMID: 29944309.
  17. Palacios R, Merchante N, Macias J, González M, Castillo J, Ruiz J, Márquez M, Gómez-Mateos J, Pineda JA, Santos J. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir Ther. 2006;11(4):529-35. PMID: 16856627.
  18. Centres for disease control and prevention: HIV surveillance Report. 2014; 26:101. http//www.cdc.gov/hiv/library/reports/surveillance/.
  19. Arthi V, Fenske J. Polygamy and child mortality: Historical and modern evidence from Nigeria’s Igbo. Rev Econ Household . 2018;16: 97–141. https://doi.org/10.1007/s11150-016-9353-x
  20. Collazos J, Ibarra S, Mayo J. Thyroid hormones in HIV-infected patients in the highly active antiretroviral therapy era: evidence of an interrelation between the thyroid axis and the immune system. AIDS. 2003 Mar 28;17(5):763-5. doi: 10.1097/00002030-200303280-00019. PMID: 12646804.
  21. Palanisamy P, Perisamy M, Uma M, Mathiyalagan D. Thyroid function, cardiac risk assessment profile and haematological changes during HIV infection and AIDS patients. J Medicine. 2010;11(2):131-36.
  22. Abbiyesuku FM, Osuji KC, Kuti MO, Atiba AS. Thyroid function tests in Nigerian HIV-Seropositive patients on highly active antiretroviral therapy (HAART). International Journal of Medical and Clinical Research. 2014;5(1):277-81.
  23. Qureshi A, Panahloo A, Seal LJ. Thyroid dysfunction in HIV. Endocrine Abstracts. 2005; 10:95.
  24. Hoffmann CJ, Brown TT. Thyroid function abnormalities in HIV-infected patients. Clin Infect Dis. 2007 Aug 15;45(4):488-94. doi: 10.1086/519978. Epub 2007 Jun 28. PMID: 17638201.
  25. Noureldeen AF, Qusti SY, Khoja GM. Thyroid function in newly diagnosed HIV-infected patients. Toxicol Ind Health. 2014 Nov;30(10):919-25. doi: 10.1177/0748233712466133. Epub 2012 Nov 27. PMID: 23188649.
  26. Verma RK, Giri R, Guputa C, Srivastava V. Study of thyroid profile in seropositive HIV adults patients on HAART regimen. Int J Adv Med. 2017; 4:1092-8.
  27. Ji S, Jin C, Höxtermann S, Fuchs W, Xie T, Lu X, Wu H, Cheng L, Skaletz-Rorowski A, Brockmeyer NH, Wu N. Prevalence and Influencing Factors of Thyroid Dysfunction in HIV-Infected Patients. Biomed Res Int. 2016;2016:3874257. doi: 10.1155/2016/3874257. Epub 2016 Apr 20. PMID: 27200374; PMCID: PMC4855012.
  28. Ketsamathi C, Jongjaroenprasert W, Chailurkit LO, Udomsubpayakul U, Kiertiburanakul S. Prevalence of thyroid dysfunction in Thai HIV-infected patients. Curr HIV Res. 2006 Oct;4(4):463-7. doi: 10.2174/157016206778560036. PMID: 17073621.
  29. Uloko AE, Abubakar UI, Gezawa ID. Thyroid Disorders and Autoimmunity among Patients with HIV/AIDS in Northern Nigeria. Ann Clin Diabetes Endocrinol. 2020;3(1):1014.
  30. Gagnon F, Langlois MF, Michaud I, Gingras S, Duchesne JF, Lévesque B. Spatio-temporal distribution of hypothyroidism in Quebec. Chronic Dis Can. 2006;27(1):1-8. PMID: 16672134.
  31. Silva GA, Andrade MC, Sugui Dde A, Nunes RF, Pinto JF, Eyer Silva WA, Ferry FR, Azevedo MC, Motta RN. Association between antiretrovirals and thyroid diseases: a cross-sectional study. Arch Endocrinol Metab. 2015 Apr;59(2):116-22. doi: 10.1590/2359-3997000000023. Epub 2015 Apr 1. PMID: 25993673.
  32. Rasoolinejad M, Afhami S, Izadi M, Hajabdolbaghi M, Kjairandish P. Clinical and paraclinical manifestation of thyroid dysfunction among patients with HIV/AIDS Tehran, Iran; 2004

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?